ABSTRACT Sodium metabisulphite (SMBS) are inserted in the operating theatre and are flushed on a continuous basis thereafter with a solution of 5 % dextrose, to which heparin is added at a concentration of 2 u/ml. This solution is supplied from a 500 ml bag, and is running at a rate of 2 ml/hour. A monitor prevents the flow rate exceeding 8 ml/hour. The reservoir bag is changed every 24 hours.
In an earlier report from this unit it was found that the use of inotropic agents via the right atrial catheter resulted in apparent protection against bacterial colonisation.1 This protective effect was traced to the sodium metabisulphite (SMBS) incorporated into the inotropic agent solution as an anti-oxidant. It is well known that SMBS is an antiseptic agent,2 and the substance is widely used in food preservation. Thus, open-heart surgical patients had been receiving a mild intravenous antiseptic for many years, without apparent adverse effects. It was thought desirable, therefore, to assess the effects of adding SMBS in similar concentration to other catheters in these patients. In particular, the effects on bacterial colonisation of the left atrial catheter tip were to be assessed since this catheter overlies the newly implanted valve in many cases.
Methods
All adult patients undergoing open-heart surgery and in whom left atrial catheters were inserted were included, and were consecutive cases. The postoperative care which such patients receive is reasonably standardised and common to the patients of all three surgeons involved in this study. The catheters are inserted in the operating theatre and are flushed on a continuous basis thereafter with a solution of 5 % dextrose, to which heparin is added at a concentration of 2 u/ml. This solution is supplied from a 500 ml bag, and is running at a rate of 2 ml/hour. A monitor prevents the flow rate exceeding 8 ml/hour. The reservoir bag is changed every 24 hours.
Sodium metabisulphite was prepared in the pharmacy as a sterile 5 % solution, stored under nitrogen, and dispensed into 5 ml aliquots. The addition of one aliquot to a 500 ml bag of dextrose (together with the heparin) thus produced a solution of 0-05 % SMBS in dextrose-heparin. This solution was used to flush left atrial catheters in the study group (see below) in an identical manner to the control groups, the bags being changed at the usual interval.
One hundred and fifty-seven patients were included, 36 The evidence that SMBS exerts a genuine protection against bacterial colonisation of the catheter tip is further strengthened by analysing the results according to the time in situ of each catheter. Thus, the only two isolations made from the SMBS treated group were obtained on days 3 and 6 (table 2). From previous data4 it is likely that the risk of colonisation increases substantially with time, and it may be that the concentration of SMBS selected for this initial trial is capable of protecting against the challenge of bacterial colonisation experienced in the first few days in situ, but that repeated and increasing bacterial contamination will eventually overcome the antiseptic. This last point may reflect our unpublished laboratory observations, in which SMBS at 0 05 % inhibited 103 staphylococci/ml but not 105 staphylococci/mI. If the results presented in table 2 are restricted to the first two days in situ (a period which includes 91 % of the catheters studied, and which would embrace almost all "'routine" admissions to the Intensive Care Unit) it can be seen that bacterial colonisation is eliminated from the SMBS-treated patients, compared with an isolation rate of 22-6% and 22 1 % for the controls.
It is important to examine the limitations of this study. Firstly, although comparative it is not truly random. It was thought that this study would be useful as a pilot trial, and that it should be analysed when it appeared that some discernible effect or lack of effect resulted. This modest objective has now been achieved with a significant difference in favour of the SMBS-treated group. Secondly, the concentration of SMBS used (0-05 %) is lower than that used in inotropic solutions (0 I%). This was selected on the basis that many of these patients would also be receiving SMBS as part of inotropic therapy. Thus, any one patient might receive SMBS from two sources and, therefore, the total daily intakeofSMBS needed to be calculated. The World Health Organisation has suggested that the daily intake of bisulphite should not exceed 700 )ug/kg/day, expressed as equivalents of S02.2 Calculation reveals that 01 0% SMBS given in the left atrial flush would introduce 480 ,sg/kg/day and thus would leave little room for a second route, especially if inotropic therapy was intensive. It is, however, clear that the WHO figure is only a suggestion and not derived from direct toxicity studies, and it remains possible that a higher concentration might be used. No biochemical or haematological insult could be found in this study.
A final, very important, limitation is that SMBS is a reducing agent and cannot, therefore, be added to complex intravenous solutions. Thus, it is likely that it will adversely react with proteins and should not 
